Primary tabs
Revisions allow you to track differences between multiple versions of your content, and revert back to older versions.
| Revision | Operations | |
|---|---|---|
| 02-7-25 by ripal121 ripal121 replaced Intermittent HD assumes high-flux hemodialysis. CRRT assumes CVVHD with ultrafiltration rate 2L/h and residual native GFR with Intermittent HD assumes high-flux hemodialysis. CRRT assumes CVVHD with ultrafiltration rate 2L/h and residual native GFR < 10 mL/min. via Scanner Search and Replace module. | current revision | |
| 02-7-25 by ripal121 ripal121 replaced Intermittent HD with Intermittent HD assumes high-flux hemodialysis. CRRT assumes CVVHD with ultrafiltration rate 2L/h and residual native GFR < 10 mL/min. via Scanner Search and Replace module. | ||
| 02-7-25 by conan.macdougal... [email protected] replaced For detailed view of dialysis dosing and evidence, see <a href="https://idmp.ucsfsitebuilder.acsitefactory.com/content/ucsf-adult-antimicrobial-dosing-dialysis-reference-document">Dosing in Hemodialysis</a> document.</p> with via Scanner Search and Replace module. | ||
| 11-4-24 by [email protected] | ||
| 07-20-23 by ripal121 | ||
| 09-21-22 by conan.macdougal... | ||
| 09-21-22 by conan.macdougal... | ||
| 09-21-22 by conan.macdougal... | ||
Dosing: Adult Antimicrobial Dosing, Non-dialysis
| Indication | ||
|---|---|---|
| All Indications | 400 mg PO BID | No adjustment for renal dysfunction |
Dosing: Antimicrobial Dosing in Intermittent & Continuous Hemodialysis
|
Indication |
Intermittent Hemodialysis |
Continuous Hemodialysis |
|---|---|---|
| All Indications | No data; consider using standard 400 mg PO BID | No data; consider using standard 400 mg PO BID |
Dialysis Notes
Dose increase required when administered with drug metabolizing enzyne inducers.
Restricted to ID or Antimicrobial Stewardship except:
1) Continuation of prior therapy
ZSFG: Non-formulary
References:
Robin K Avery, Sophie Alain, Barbara D Alexander, Emily A Blumberg, Roy F Chemaly, Catherine Cordonnier, Rafael F Duarte, Diana F Florescu, Nassim Kamar, Deepali Kumar, Johan Maertens, Francisco M Marty, Genovefa A Papanicolaou, Fernanda P Silveira, Oliver Witzke, Jingyang Wu, Aimee K Sundberg, Martha Fournier, SOLSTICE Trial Investigators, Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial, Clinical Infectious Diseases, Volume 75, Issue 4, 15 August 2022, Pages 690–701, https://doi.org/10.1093/cid/ciab988